Prasugrel.
Huber
Kurt
K
Yasothan
Uma
U
Hamad
Bashar
B
Kirkpatrick
Peter
P
D004311:Double-Blind Method; D015195:Drug Design; D004345:Drug Industry / Q000379:methods; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000138:chemical synthesis / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000138:chemical synthesis / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D058919:Purinergic P2 Receptor Antagonists; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D013876:Thiophenes / Q000009:adverse effects / Q000138:chemical synthesis / Q000627:therapeutic use*
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride